Want to see CH:GALD full AI Analyst Report?
GALD Stock Chart & Stats
CHF156.85
-CHF8.02(-7.15%)
At close: 4:00 PM EST
CHF156.85
-CHF8.02(-7.15%)
Day’s Range― - ―
52-Week RangeCHF122.70 - CHF188.25
Previous CloseN/A
Volume230.69K
Average Volume (3M)337.59K
Market Cap
CHF40.95B
Enterprise ValueCHF52.72B
Total Cash (Recent Filing)CHF780.00M
Total Debt (Recent Filing)CHF2.75B
Price to Earnings (P/E)80.1
Beta0.78
Next Earnings
Jul 23, 2026EPS Estimate
1.43Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)2.69
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF194.00Price Target Upside23.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)4.63
Revenue Forecast (FY)CHF6.32B
Bulls Say, Bears Say
Bulls Say
High Gross Margins And ProfitabilityConsistently high gross margins (~67–70%) and a multi-year swing to net profitability create durable margin headroom. Higher gross margins plus improved operating leverage (EBIT margin rose meaningfully) support sustained earnings and fund reinvestment, making profitability less reliant on volume alone.
Strong Recent Cash GenerationLarge operating cash flow and ~1.03B FCF in 2025 materially improve financial flexibility. Reliable cash generation enables debt servicing, R&D and commercial investment, and shareholder distributions, strengthening the company's ability to execute strategy over the next several quarters.
Material Reduction In LeverageA substantially lower debt-to-equity ratio improves balance-sheet resilience and lowers financing risk. Reduced leverage increases capacity for strategic investments and cushions against cyclical downturns, supporting durable capital allocation and credit stability over the medium term.
Bears Say
Sizeable Absolute Debt BurdenDespite improved ratios, a large gross debt load (~2.75B) maintains refinancing and interest-service risk. If top-line or margin performance falters, servicing that absolute debt could constrain investment, raise financing costs, and limit strategic optionality across the medium term.
Revenue Volatility / 2025 DipA year-over-year revenue decline in 2025 while earnings improved signals potential reliance on margin gains or one-off items. Revenue inconsistency raises uncertainty about sustainable demand and growth trajectory, complicating forecasting and long-term capacity to convert profitability into durable expansion.
Prior Cash-flow InconsistencyHistorical swings—negative FCF in 2022 and weak operating cash flow in 2023–2024—indicate cash generation was not consistently reliable. The 2025 improvement, while strong, must be sustained; prior volatility implies execution and demand risks that could re-emerge within a 2–6 month horizon.
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF122.70 and its highest was CHF188.25 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF40.95B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Jul 23, 2026 which is in 11 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Mar 05, 2026. The company reported CHF1.638 earnings per share for the quarter, beating the consensus estimate of CHF1.272 by CHF0.366.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Notavailable dividend of CHF0.35 which represents an annual dividend yield of 0.09%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 1.43.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.638 in its last earnings report, beating expectations of CHF1.272. Following the earnings report the stock price went up 6.975%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
GALD Stock 12 Month Forecast
Average Price Target
CHF194.00
▲(23.69% Upside)
Technical Analysis
Options Prices
Currently, No data available
---







